Immunomodulation in infectious diarrhea
Immunomodulation in infectious diarrhea
批准号:
6559730
负责人:
JAN-MICHAEL AXEL KLAPPROTH
金额:
$12.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2008-06-30
关键词:
Clostridium Escherichia coli T cell receptor T lymphocyte bacterial toxins clinical research diarrhea gastrointestinal infection gene mutation genetically modified animals glycosyltransferase guanine nucleotide binding protein human subject immunosuppression interferon gamma interleukin 2 interleukin 4 laboratory mouse leukocyte activation /transformation mucosal immunity site directed mutagenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
The goal of the principal investigator is to continue to develop intellectual, technical, and analytical skills to become an independently funded physician-scientist investigator in microbial pathogenesis, examining the effect of bacterial products on the immune system. The program to achieve this goal will consist of additional didactic and laboratory training in basic immunology, lymphocyte signal transduction, and microbial and molecular genetics.
Bacterial immunomodulatory products are of utmost importance in infectious diseases and their prevention. For example, C. difficile toxin A and B are implicated in the development of pseudomembranous enterocolitis, and cholera toxin functions as an adjuvant in oral immunization. In this proposal we will continue to characterize a novel toxin from Enteropathogenic E. coli (EPEC), resulting in marked inhibition of T cell activation. The inhibitory gene, lifA (lymphocyte inhibitory activity), encodes for a protein with the putative size of 366kDa. The lifA gene product, lymphostatin, bears significant similarity to the N-terminus of large Clostridial cytotoxins, encoding for a glucosyltransferase motif, which is critical for their specific activity. Similar immunosuppressive genes and biological activity have been identified in related bacteria, including other EPEC strains, Enterohemorrhagic E. coli, and the mouse pathogen C. rodentium. Our hypothesis is that the glucosyltransferase motif in lymphostatin is critical for the observed immunosuppression, leading to inhibition of defined lymphocyte subpopulations of the adaptive immune response and allowing firm establishment of enteric Gram negative infection. To test the hypothesis, we propose: Aim 1: To identify the co-substrate and target molecule(s) in lymphocytes exposed to lymphostatin. Aim 2: To investigate intracellular activation pathways in defined lymphocyte populations affected by lymphostatin, resulting in suppression of IL-2, IL-4, and IFN-gamma expression. Aim 3: To investigate whether lymphostatin suppresses the mucosal adaptive immune response and firmly establishes C. rodentium enteric infection in vivo.
The proposed research project will contribute to the understanding of immune mechanisms involved in the pathogenesis of chronic infectious diarrhea and gastrointestinal inflammation as seen in Crohn's disease and ulcerative colitis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of proteins in the apical junctional complex by Citrobacter rodentium
-
批准号:8142639
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Regulation of proteins in the apical junctional complex by Citrobacter rodentium
-
批准号:8696767
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Regulation of proteins in the apical junctional complex by Citrobacter rodentium
-
批准号:8244939
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Regulation of proteins in the apical junctional complex by Citrobacter rodentium
-
批准号:8445152
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Regulation of Proteins in the Apical Junctional Complex by Citrobacter rodentium
-
批准号:7558928
-
项目类别:
-
资助金额:$6.98万
-
财政年份:2008
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Regulation of Proteins in the Apical Junctional Complex by Citrobacter rodentium
-
批准号:7382742
-
项目类别:
-
资助金额:$7.74万
-
财政年份:2008
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Immunomodulation in infectious diarrhea
-
批准号:6731993
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2003
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Immunomodulation in infectious diarrhea
-
批准号:7095912
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2003
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Immunomodulation in infectious diarrhea
-
批准号:7263889
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2003
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
Immunomodulation in infectious diarrhea
-
批准号:6894226
-
项目类别:
-
资助金额:$12.77万
-
财政年份:2003
-
负责人:JAN-MICHAEL AXEL KLAPPROTH
-
依托单位:
国内基金
海外基金
登录
查看更多内容
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
-
批准号:32302245
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:潘寒姁
-
依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
-
批准号:82371775
-
项目类别:面上项目
-
资助金额:46万元
-
批准年份:2023
-
负责人:朱慧媛
-
依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
-
批准号:31871817
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2018
-
负责人:孙爱东
-
依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
-
批准号:81873549
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:刘玉兰
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的分子机制
-
批准号:31571933
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:廖小军
-
依托单位:
超高压诱导牛肉中Escherichia coli O157:H7亚致死损伤及其修复研究
-
批准号:31371861
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:江芸
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的机制
-
批准号:31371845
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:廖小军
-
依托单位:
高密度二氧化碳致死Escherichia coli的相关蛋白质确证及其结构变化研究
-
批准号:31171774
-
项目类别:面上项目
-
资助金额:66.0万元
-
批准年份:2011
-
负责人:张德权
-
依托单位: